Form 4: HCA CFO Marks Granted Stock Appreciation Rights

HCA Healthcare's EVP and CFO, Mike A. Marks, was granted 11,945 stock appreciation rights with an exercise price of $482.53, vesting over four years.

Summary

• Mike A. Marks, Executive Vice President and Chief Financial Officer of HCA Healthcare, Inc., was granted 11,945 Stock Appreciation Rights (SARs).
• The transaction occurred on January 29, 2026.
• The exercise price for these SARs is $482.53 per share.
• The SARs vest in four equal annual installments, commencing on January 29, 2027.
• The expiration date for these SARs is January 29, 2036.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a standard executive compensation practice that aligns management's interests with shareholder value creation, without indicating any immediate operational or financial changes.

Positives

• The grant of Stock Appreciation Rights aligns the executive's interests with long-term shareholder value creation.
• The vesting schedule over four years encourages executive retention and sustained performance.

Negatives

• No inherently negative information is presented in this routine executive compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's operational or financial performance, beyond the vesting schedule of the granted stock appreciation rights.

Industry Context

StockSavvy.ai notes that the grant of Stock Appreciation Rights to a key executive like the CFO is a common practice in the healthcare industry and broader corporate landscape. It serves as a performance incentive and retention tool, aligning executive compensation with the company's stock performance, similar to practices seen at peers like Universal Health Services or Tenet Healthcare.

Comparison to Industry Standards

• The grant of Stock Appreciation Rights (SARs) is a standard component of executive compensation packages across various industries, including healthcare, comparable to grants at companies like Universal Health Services (UHS) or Community Health Systems (CHS).
• A four-year vesting schedule is typical for long-term incentive awards, designed to promote executive retention and long-term value creation, aligning with best practices observed in major S&P 500 companies.
• The use of a Rule 10b5-1(c) plan for the transaction indicates a pre-arranged, compliant approach to insider trading, a common and recommended practice for executives to manage their equity holdings.

Stakeholder Impact

• Shareholders: The grant of SARs aligns the CFO's incentives with shareholder value, as the SARs gain value only if the stock price increases. However, SARs can lead to potential dilution upon exercise, though less direct than stock options.
• Employees: No direct impact on general employees is indicated by this executive compensation filing.
• Management: The CFO receives a significant long-term incentive, potentially increasing motivation and retention.

Next Steps

• The Stock Appreciation Rights will begin vesting in four equal annual installments starting January 29, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant and does not contain information that would typically warrant a change in investment recommendation. It is a standard disclosure of an insider transaction designed to align executive incentives with long-term company performance, rather than a signal for immediate stock price movement.

Keywords

HCA Healthcare, Mike A. Marks, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, Form 4, HCA